{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T01:38:24Z","timestamp":1792460304357,"version":"4.5.0"},"reference-count":20,"publisher":"American Diabetes Association","issue":"2","license":[{"start":{"date-parts":[[2022,11,10]],"date-time":"2022-11-10T00:00:00Z","timestamp":1668038400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.diabetesjournals.org\/journals\/pages\/license"}],"funder":[{"DOI":"10.13039\/501100007543","name":"Agence Nationale de S\u00e9curit\u00e9 du M\u00e9dicament et des Produits de Sant\u00e9","doi-asserted-by":"publisher","award":["2019S015"],"award-info":[{"award-number":["2019S015"]}],"id":[{"id":"10.13039\/501100007543","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["diabetesjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,2,1]]},"abstract":"<jats:sec>\n                    <jats:title>OBJECTIVE<\/jats:title>\n                    <jats:p>To determine whether use of glucagon-like peptide 1 (GLP-1) receptor agonists (RA) is associated with increased risk of thyroid cancer.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESEARCH DESIGN AND METHODS<\/jats:title>\n                    <jats:p>A nested case-control analysis was performed with use of the French national health care insurance system (SNDS) database. Individuals with type 2 diabetes treated with second-line antidiabetes drugs between 2006 and 2018 were included in the cohort. All thyroid cancers were identified through hospital discharge diagnoses and medical procedures between 2014 and 2018. Exposure to GLP-1 RA was measured within the 6 years preceding a 6-month lag-time period and considered as current use and cumulative duration of use based on defined daily dose (\u22641, 1 to 3, &amp;gt;3 years). Case subjects were matched with up to 20 control subjects on age, sex, and length of diabetes with the risk-set sampling procedure. Risk of thyroid cancer related to use of GLP-1 RA was estimated with a conditional logistic regression with adjustment for goiter, hypothyroidism, hyperthyroidism, other antidiabetes drugs, and social deprivation index.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS<\/jats:title>\n                    <jats:p>A total of 2,562 case subjects with thyroid cancers were included in the study and matched with 45,184 control subjects. Use of GLP-1 RA for 1\u20133 years was associated with increased risk of all thyroid cancer (adjusted hazard ratio [HR] 1.58, 95% CI 1.27\u20131.95) and medullary thyroid cancer (adjusted HR 1.78, 95% CI 1.04\u20133.05).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSIONS<\/jats:title>\n                    <jats:p>In the current study we found increased risk of all thyroid cancer and medullary thyroid cancer with use of GLP-1 RA, in particular after 1\u20133 years of treatment.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2337\/dc22-1148","type":"journal-article","created":{"date-parts":[[2022,11,10]],"date-time":"2022-11-10T13:55:12Z","timestamp":1668088512000},"page":"384-390","update-policy":"https:\/\/doi.org\/10.2337\/ada-journal-policies","source":"Crossref","is-referenced-by-count":304,"title":["GLP-1 Receptor Agonists and the Risk of Thyroid Cancer"],"prefix":"10.2337","volume":"46","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2568-1928","authenticated-orcid":false,"given":"Julien","family":"Bezin","sequence":"first","affiliation":[{"name":"1Service de Pharmacologie, P\u00f4le de Sant\u00e9 Publique, Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France"},{"name":"2UMR 1219, Pharmacoepidemiology Team, Bordeaux Population Health Research Center, Inserm, University of Bordeaux, Bordeaux, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amandine","family":"Gouverneur","sequence":"additional","affiliation":[{"name":"1Service de Pharmacologie, P\u00f4le de Sant\u00e9 Publique, Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France"},{"name":"2UMR 1219, Pharmacoepidemiology Team, Bordeaux Population Health Research Center, Inserm, University of Bordeaux, Bordeaux, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marine","family":"P\u00e9nichon","sequence":"additional","affiliation":[{"name":"2UMR 1219, Pharmacoepidemiology Team, Bordeaux Population Health Research Center, Inserm, University of Bordeaux, Bordeaux, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cl\u00e9ment","family":"Mathieu","sequence":"additional","affiliation":[{"name":"2UMR 1219, Pharmacoepidemiology Team, Bordeaux Population Health Research Center, Inserm, University of Bordeaux, Bordeaux, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renaud","family":"Garrel","sequence":"additional","affiliation":[{"name":"3Service de Chirurgie ORL, Centre Hospitalier Universitaire de Montpellier, Montpellier, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominique","family":"Hillaire-Buys","sequence":"additional","affiliation":[{"name":"4D\u00e9partement de Pharmacologie M\u00e9dicale et Toxicologie, Centre Hospitalier Universitaire de Montpellier, Montpellier, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoine","family":"Pariente","sequence":"additional","affiliation":[{"name":"1Service de Pharmacologie, P\u00f4le de Sant\u00e9 Publique, Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France"},{"name":"2UMR 1219, Pharmacoepidemiology Team, Bordeaux Population Health Research Center, Inserm, University of Bordeaux, Bordeaux, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Luc","family":"Faillie","sequence":"additional","affiliation":[{"name":"4D\u00e9partement de Pharmacologie M\u00e9dicale et Toxicologie, Centre Hospitalier Universitaire de Montpellier, Montpellier, France"},{"name":"5INSERM, Universit\u00e9\u00a0de\u00a0Montpellier, Institut Desbrest d\u2019\u00c9pid\u00e9miologie et de Sant\u00e9 Publique, Montpellier, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1167","published-online":{"date-parts":[[2022,11,10]]},"reference":[{"key":"2023012619552131400_B1","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1053\/gast.2002.31068","article-title":"Biological actions and therapeutic potential of the glucagon-like peptides","volume":"122","author":"Drucker","year":"2002","journal-title":"Gastroenterology"},{"key":"2023012619552131400_B2","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1210\/en.2009-1272","article-title":"Glucagon-like peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation","volume":"151","author":"Bjerre Knudsen","year":"2010","journal-title":"Endocrinology"},{"key":"2023012619552131400_B3","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.ejphar.2012.07.024","article-title":"Effect of exendin (exenatide)--GLP 1 receptor agonist on the thyroid and parathyroid gland in a rat model","volume":"691","author":"Bulchandani","year":"2012","journal-title":"Eur J Pharmacol"},{"key":"2023012619552131400_B4","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.1210\/en.2014-1722","article-title":"Chronic toxicity and carcinogenicity studies of the long-acting GLP-1 receptor agonist dulaglutide in rodents","volume":"156","author":"Byrd","year":"2015","journal-title":"Endocrinology"},{"key":"2023012619552131400_B5","unstructured":"European Medicines Agency\n          . Trulicity, 2018. Accessed 31 January 2020. Available from https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/trulicity"},{"key":"2023012619552131400_B6","unstructured":"European Medicines Agency\n          . Victoza, 2018. Accessed 31 January 2020. Available from https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/victoza"},{"key":"2023012619552131400_B7","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.2337\/dc17-1825","article-title":"Neoplasms reported with liraglutide or placebo in people with type 2 diabetes: results from the LEADER randomized trial","volume":"41","author":"Nauck","year":"2018","journal-title":"Diabetes Care"},{"key":"2023012619552131400_B8","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.diabres.2012.09.008","article-title":"A meta-analysis of serious adverse events reported with exenatide and liraglutide: acute pancreatitis and cancer","volume":"98","author":"Alves","year":"2012","journal-title":"Diabetes Res Clin Pract"},{"key":"2023012619552131400_B9","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1177\/2042098612446473","article-title":"Incidence of health insurance claims for thyroid neoplasm and pancreatic malignancy in association with exenatide: signal refinement using active safety surveillance","volume":"3","author":"Dore","year":"2012","journal-title":"Ther Adv Drug Saf"},{"key":"2023012619552131400_B10","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1111\/dom.13597","article-title":"Exenatide use and incidence of pancreatic and thyroid cancer: a retrospective cohort study","volume":"21","author":"Liang","year":"2019","journal-title":"Diabetes Obes Metab"},{"key":"2023012619552131400_B11","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1002\/pds.4233","article-title":"The national healthcare system claims databases in France, SNIIRAM and EGB: powerful tools for pharmacoepidemiology","volume":"26","author":"Bezin","year":"2017","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2023012619552131400_B12","unstructured":"WHO Collaborating Centre for Drug Statistics Methodology\n          . ATC\/DDD Index. Accessed 25 October 2021. Available from https:\/\/www.whocc.no\/atc_ddd_index\/?code=L04AA&showdescription=no"},{"key":"2023012619552131400_B13","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1214\/aos\/1176348895","article-title":"Asymptotic theory for nested case-control sampling in the Cox regression model","volume":"20","author":"Goldstein","year":"1992","journal-title":"Ann Stat"},{"key":"2023012619552131400_B14","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/1471-2288-5-5","article-title":"Comparison of nested case-control and survival analysis methodologies for analysis of time-dependent exposure","volume":"5","author":"Essebag","year":"2005","journal-title":"BMC Med Res Methodol"},{"key":"2023012619552131400_B15","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/pds.668","article-title":"A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions","volume":"11","author":"van Puijenbroek","year":"2002","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2023012619552131400_B16","doi-asserted-by":"crossref","first-page":"620","DOI":"10.2337\/dc17-1956","article-title":"No evidence of increase in calcitonin concentrations or development of C-cell malignancy in response to liraglutide for up to 5 years in the LEADER trial","volume":"41","author":"Heged\u00fcs","year":"2018","journal-title":"Diabetes Care"},{"key":"2023012619552131400_B17","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.2337\/dc18-2028","article-title":"Changes in serum calcitonin concentrations, incidence of medullary thyroid carcinoma, and impact of routine calcitonin concentration monitoring in the EXenatide Study of Cardiovascular Event Lowering (EXSCEL)","volume":"42","author":"Bethel","year":"2019","journal-title":"Diabetes Care"},{"key":"2023012619552131400_B18","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1053\/j.gastro.2011.02.018","article-title":"Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies","volume":"141","author":"Elashoff","year":"2011","journal-title":"Gastroenterology"},{"key":"2023012619552131400_B19","doi-asserted-by":"crossref","first-page":"2684","DOI":"10.3892\/ol.2017.5752","article-title":"Expression of GLP-1 receptor and CD26 in human thyroid C-cells: the association of thyroid C-cell tumorigenesis with incretin-based medicine","volume":"13","author":"Song","year":"2017","journal-title":"Oncol Lett"},{"key":"2023012619552131400_B20","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1159\/000330447","article-title":"Incretin receptors in non-neoplastic and neoplastic thyroid C cells in rodents and humans: relevance for incretin-based diabetes therapy","volume":"94","author":"Waser","year":"2011","journal-title":"Neuroendocrinology"}],"container-title":["Diabetes Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/diabetesjournals.org\/care\/article-pdf\/46\/2\/384\/696511\/dc221148.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/diabetesjournals.org\/care\/article-pdf\/46\/2\/384\/696511\/dc221148.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,26]],"date-time":"2023-01-26T14:55:54Z","timestamp":1674744954000},"score":1,"resource":{"primary":{"URL":"https:\/\/diabetesjournals.org\/care\/article\/46\/2\/384\/147888\/GLP-1-Receptor-Agonists-and-the-Risk-of-Thyroid"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,10]]},"references-count":20,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2022,11,10]]},"published-print":{"date-parts":[[2023,2,1]]}},"URL":"https:\/\/doi.org\/10.2337\/dc22-1148","relation":{},"ISSN":["0149-5992","1935-5548"],"issn-type":[{"value":"0149-5992","type":"print"},{"value":"1935-5548","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,10]]}}}